Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GX-70 in High Risk Pulmonary Tuberculosis
NCT03159975Phase 1Withdrawn
- Sponsor
- Yonsei University
- Start
- Mar 2018
- Primary completion
- Aug 2018
- Modality
- Prophylactic Vaccines, DNA Vaccines
01
Overview
Phase 1, open-label trial of GX-70 in pulmonary tuberculosis (TB) (3 arms), sponsored by Yonsei University. Primary endpoint: Maximum Tolerant Dose at 16 weeks. Planned start Mar 2018; status: withdrawn.
02
Drugs
GX-70
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT03159975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159975.